<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://www.2minutemedicine.com/feed/</title><link>https://www.2minutemedicine.com/feed/</link><description>Individual feed output.</description><lastBuildDate>Fri, 05 Sep 2025 06:48:10 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Computed Tomographic Angiography and Yield for Gastrointestinal Bleeding in the Emergency Department</title><link>https://www.2minutemedicine.com/computed-tomographic-angiography-and-yield-for-gastrointestinal-bleeding-in-the-emergency-department/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2020/07/ambulance_cc_2_edited-300x150.jpg</image_url><description>1. Between the years 2017 and 2023, the proportion of total computed tomographic angiography (CTA) examinations related to gastrointestinal bleeding (...</description><pubDate>Fri, 05 Sep 2025 00:00:03 GMT</pubDate></item><item><title>Novo’s self replicating RNA push expands cardiometabolic pipeline</title><link>https://www.2minutemedicine.com/novos-self-replicating-rna-push-expands-cardiometabolic-pipeline/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2013/07/US_Navy_110727-N-YR391-005_Lt._Cmdr._Jennifer_Freeman_an_Obstetrics-Gynecology_physician_at_Naval_Hospital_Jacksonville-300x150.jpg</image_url><description>1. Novo Nordisk expanded into self replicating RNA for obesity and T2D (type 2 diabetes), signaling modality diversification beyond peptides. 2. The c...</description><pubDate>Thu, 04 Sep 2025 15:00:02 GMT</pubDate></item><item><title>Long-term Outcomes of Patients with Crohn’s Disease Treated with Risankizumab</title><link>https://www.2minutemedicine.com/long-term-outcomes-of-patients-with-crohns-disease-treated-with-risankizumab/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2018/12/Crohn_Colitis_6264520294-300x150.jpg</image_url><description>1. In adult patients with Crohn’s disease (CD) treated with risankizumab, only 13% of patients experienced treatment failure while 23% of patients req...</description><pubDate>Thu, 04 Sep 2025 00:00:59 GMT</pubDate></item><item><title>2 Minute Medicine: Pharma Roundup- Obesity RNA deal, at-home Alzheimer’s dosing, oncology royalty financing, and first Bruton’s Tyrosine Kinase Inhibitor for Immune Thrombocytopenia [September 3, 2025]</title><link>https://www.2minutemedicine.com/2-minute-medicine-pharma-roundup-obesity-rna-deal-at-home-alzheimers-dosing-oncology-royalty-financing-and-first-brutons-tyrosine-kinase-inhibitor-for-immune-thrombocytopenia-s/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-300x200.png</image_url><description>Novo’s srRNA push expands cardiometabolic pipeline On August 28, Novo Nordisk announced a collaboration with Replicate Bioscience to pursue self repli...</description><pubDate>Wed, 03 Sep 2025 16:50:58 GMT</pubDate></item><item><title>Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study</title><link>https://www.2minutemedicine.com/menin-inhibition-with-revumenib-for-npm1-mutated-relapsed-or-refractory-acute-myeloid-leukemia-the-augment-101-study-1-in-pretreated-patients-with-nucleophosmin-1-mutated-npm1m-acute-myeloid-leuke/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2017/03/chronic-myelogenous-leukemia-300x150.jpg</image_url><description>1. In pretreated patients with nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML), nearly half of patients treated with revumenib showed a c...</description><pubDate>Wed, 03 Sep 2025 00:00:12 GMT</pubDate></item></channel></rss>